Valuation: IN8bio, Inc.

Market Cap 13.8M 12.26M 11.45M 10.43M 19.67M 1.33B 19.86M 139M 53.67M 678M 51.82M 50.69M 2.18B P/E 2026 *
-1.26x
P/E 2027 * -1.47x
Enterprise Value 13.8M 12.26M 11.45M 10.43M 19.67M 1.33B 19.86M 139M 53.67M 678M 51.82M 50.69M 2.18B EV / Sales 2026 *
-
EV / Sales 2027 * 12.5x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 week+16.67%
Current month+5.26%
1 month+20.69%
3 months-1.41%
6 months-2.78%
Current year-40.17%
1 week 1.19
Extreme 1.19
1.46
1 month 1.01
Extreme 1.01
1.46
Current year 0.88
Extreme 0.88
2.73
1 year 0.88
Extreme 0.88
2.73
3 years 0.88
Extreme 0.88
74.4
5 years 0.88
Extreme 0.88
282.72
10 years 0.88
Extreme 0.88
309.57
Manager TitleAgeSince
Chief Executive Officer 50 01/11/2015
Chief Tech/Sci/R&D Officer 72 01/11/2018
Director of Finance/CFO 43 08/02/2021
Director TitleAgeSince
Director/Board Member 50 01/11/2015
Director/Board Member 68 01/07/2019
Director/Board Member 64 04/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Don

Director

-724,637 7.3589%
09/05/26 Free

Chairman

22,000 0.2234%
09/05/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+16.67%-41.42%-95.60% 13.8M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.20%+1.14%+43.23%+106.13% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.95%+138.25%

Financials

2026 *2027 *
Net sales - 1.11M 983K 917K 836K 1.58M 106M 1.59M 11.1M 4.3M 54.37M 4.15M 4.06M 174M
Net income -20.96M -18.63M -17.38M -15.85M -29.88M -2.02B -30.16M -210M -81.52M -1.03B -78.71M -77M -3.31B -23.72M -21.08M -19.67M -17.93M -33.82M -2.28B -34.14M -238M -92.26M -1.17B -89.08M -87.14M -3.74B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
02/10/26 $1.400 0.00% 39,473
01/10/26 $1.400 +5.26% 78,466
30/09/26 $1.330 +2.70% 30,299
29/09/26 $1.295 +4.44% 62,212
28/09/26 $1.240 +3.33% 74,348
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.400USD
Average target price
7.000USD
Spread / Average Target
+400.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock